Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02436759 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
A Phase 3 study of Acquired Blepharoptosis, sponsored by RVL Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 14
- Study locations
NCT02436759: Completed Phase 3 study of Acquired Blepharoptosis, sponsored by RVL Pharmaceuticals.
NCT02436759 is a Phase 3 study of Acquired Blepharoptosis that has completed, run by RVL Pharmaceuticals. The registered enrollment target is 140 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02436759, a Phase 3 study of Acquired Blepharoptosis, has completed, sponsored by RVL Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.
Primary Outcome
LPFT Total Score is the number of points seen in the top 4 rows on the LPFT. Possible scores range from 0 (no points seen) to 35 (all points seen).
Conditions Studied
Interventions
- DRUG RVL-1201
- DRUG RVL-1201 Vehicle Placebo
Study Locations (14)
California
- - Artesia
- - Newport Beach
- - Rancho Cordova
- - Santa Maria
Florida
- - Fort Myers
- - Largo
- - Plantation
- - Sarasota
Kansas
- - Pittsburg
- - Shawnee Mission
Georgia
- - Roswell
Ohio
- - Mason
Pennsylvania
- - Kingston
Tennessee
- - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
What the finished NCT02436759 record still lists
NCT02436759 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Acquired Blepharoptosis appearing as the primary indexed condition, and to 2 interventions - of which RVL-1201 is the first listed.
NCT02436759 lists 14 locations in 7 states (California, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT02436759 about?
NCT02436759 is a clinical study titled "Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis". This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.
What is the current status of trial NCT02436759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2015-05. Estimated completion is 2016-11.
What conditions does trial NCT02436759 study?
This clinical trial studies the following conditions: Acquired Blepharoptosis.
What interventions are being tested in trial NCT02436759?
The interventions under investigation include: RVL-1201 (DRUG), RVL-1201 Vehicle Placebo (DRUG).
Who is sponsoring clinical trial NCT02436759?
This trial is sponsored by RVL Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02436759 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02436759's enrollment target sits among peer trials
140 1565th of 2000 higher than 424 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia